(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
What's your #1 tone - 2Is new Harry Styles music on the way? Fans think so, after a cryptic website and posters pop up.
- 3Day to day Temporary Positions That Compensate Fairly in the US
- 4Sustaining Public activity and Connections: Key Methodologies
- 5Tatiana Schlossberg, JFK's granddaughter, dies at 35 after terminal cancer diagnosis
- Conquering Language Boundaries: Individual Accounts of Multilingualism
- One of the best meteor showers of the year peaks at the worst possible time this week
- Dental, Vision, and Hearing Inclusion in Senior Protection.
- Taco Bell debuts its Baja Blast pie, and the reactions may surprise you
- 6 Exemplary Mexican Dishes
- The last penny was pressed by the U.S. Mint in Philadelphia today. Could the nickel and dime be next?
- Find the Advantages of Positive Nurturing: Supporting Cheerful and Sound Kids
- A definitive Manual for Well known Fragrances
- Cheetos and Doritos to launch new versions without artificial dyes
